Kevin John Whitehead
Physician in Salt Lake City, UT
License number
Utah 364493-1205
Issued Date
Oct 2, 1998
Expiration Date
Jan 31, 2018
Category
Physician
Type
Physician & Surgeon
Address
Address
Salt Lake City, UT
Personal information
See more information about Kevin John Whitehead at radaris.comName
Address
Phone
4872 S 2475 W, Salt Lake City, UT 84129
4764 S Quail Point Rd, Salt Lake City, UT 84124
4764 Quail Point Rd, Salt Lake City, UT 84124
164 N 300 E, Lehi, UT 84043
298 S Staci Ct, Cedar City, UT 84720
Professional information
Kevin Whitehead, Salt Lake City UT
Work:
Uumc Cardiology
50 N Medical Dr, Salt Lake City, UT 84132 Va Salt Lake City Health Care System
500 Foothill Dr, Salt Lake City, UT 84148 School of Medicine
30 N Medical Dr, Salt Lake City, UT 84132 University of Utah Hospitals & Clinics
1525 W 2100 S, Salt Lake City, UT 84119 Childrens Hospital of Philadelphia
34th Civic Center Blvd, Philadelphia, PA 19104 George and Dolores Eccles Institute of Human Genetics
15 N 2030 E, Salt Lake City, UT 84112
50 N Medical Dr, Salt Lake City, UT 84132 Va Salt Lake City Health Care System
500 Foothill Dr, Salt Lake City, UT 84148 School of Medicine
30 N Medical Dr, Salt Lake City, UT 84132 University of Utah Hospitals & Clinics
1525 W 2100 S, Salt Lake City, UT 84119 Childrens Hospital of Philadelphia
34th Civic Center Blvd, Philadelphia, PA 19104 George and Dolores Eccles Institute of Human Genetics
15 N 2030 E, Salt Lake City, UT 84112
Pharmacological Targeting Of Vascular Malformations
US Patent:
2011011, May 12, 2011
Filed:
Apr 16, 2009
Appl. No.:
12/937336
Inventors:
Dean Li - Salt Lake City UT, US
Kevin Whitehead - Salt Lake City UT, US
Aubrey Chan - Salt Lake City UT, US
Nyall London - West Valley UT, US
Sutip Navankasattusas - Salt Lake City UT, US
Kevin Whitehead - Salt Lake City UT, US
Aubrey Chan - Salt Lake City UT, US
Nyall London - West Valley UT, US
Sutip Navankasattusas - Salt Lake City UT, US
Assignee:
University of Utah Research Foundation - Salt Lake City UT
International Classification:
A61K 31/675, A61K 31/366, A61K 31/663, A61K 31/4164, A61K 31/216, A61K 31/4409, A61K 31/5513, A61P 25/08, A61P 9/00, A61P 9/10
US Classification:
514 89, 514460, 514108, 514 94, 514400, 514510, 514352, 514218
Abstract:
Disclosed herein are compositions and methods for decreasing vascular permeability in a blood vessel and treating or preventing conditions associated with defects or injuries of vascular endothelium. For example, the disclosed compositions and methods can be used to treat a vascular dysplasia such as cerebral cavernous malformation (CCM). These methods relate generally to the use of compositions that inhibit RhoA GTPase levels or activity, such as inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase.